Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment pause versus continuation of pembrolizumab + axitinib in responding first-line metastatic renal cell carcinoma
2021-003447-25Phase 3Active
- Sponsor
- Centre Hospitalier Universitaire de Bordeaux
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and axitinib in renal cell carcinoma (RCC) (2 arms), sponsored by Centre Hospitalier Universitaire de Bordeaux. Started Oct 2021; status: active.
02
Drugs
pembrolizumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2021-003447-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003447-25.